Cargando…
Intraokulare Entzündungen bei Brolucizumab-Anwendung: Patientenmanagement – Diagnose – Therapie
The anti-vascular endothelial growth factor (anti-VEGF) agent brolucizumab has been approved in the USA in October 2019 and in Europe in February 2020 for the treatment of neovascular age-related macular degeneration (nAMD). The approval was based on the randomized, double-blind phase III studies HA...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935813/ https://www.ncbi.nlm.nih.gov/pubmed/33555415 http://dx.doi.org/10.1007/s00347-021-01321-8 |